Peritoneal mesotheioma. Cytoreductive surgery and HIPEC
https://doi.org/10.21294/1814-4861-2025-24-3-198-204
Abstract
Background. Peritoneal mesothelioma is a rare, high invasive and aggressive malignant tumor that arises from the mesothelial cells lining the abdominal cavity. Surgery is a primary treatment method for mesothelioma. It allows the removal of macroscopically visible tumor masses, which are often resistant to conventional drug therapy. However, the necessity and appropriateness of a surgical approach should be assessed individually, taking into account the histological subtype of the tumor, the extent of its spread and the presence of associated risk factors. Current research shows that the best long-term results are achieved with a multimodal treatment approach, which may include a combination of surgery, chemotherapy, and radiotherapy. This comprehensive approach allows for more effective management of the disease and improved quality of life of patients.
Case report. We present a clinical case of a 59year-old female patient with peritoneal mesothelioma. The patient underwent surgery with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin and doxorubicin. During a 12-month follow-up, there were no signs of disease progression, which indicates the high effectiveness of the applied approach.
Conclusion. The use of cytoreductive surgery and HIPEC demonstrated positive effects in the treatment of peritoneal mesothelioma.
About the Authors
S. M. Kopeyka
Surgut District Clinical Hospital
Russian Federation
Russian Federation
Sergei M. Kopeyka - MD, Head of the Department of Abdominal and Thoracic Oncology.
Build. 2, 24, Energetikov St., Surgut, 628408
A. A. Aksarin
Surgut District Clinical Hospital; Surgut State University
Russian Federation
Russian Federation
Aleksei A. Aksarin MD, DSc, Associate Professor, Department of Surgical Diseases, Surgut State University; Head of the Oncology Center, Surgut District Clinical Hospital.
Build. 2, 24, Energetikov St., Surgut, 628408; 1, Lenin Ave., Surgut, 628403
M. Y. Babenko
Surgut District Clinical Hospital
Russian Federation
Russian Federation
Maksim Yu. Babenko - MD, Pathologist, Pathology Department.
Build. 2, 24, Energetikov St., Surgut, 628408
References
1. Greenbaum A., Alexander H.R. Peritoneal mesothelioma. Transl Lung Cancer Res. 2020; 9(s1): 120–32. doi: 10.21037/tlcr.2019.12.15.
2. Malpica A. Peritoneal Mesothelioma-An Update. Adv Anat Pathol. 2023; 30(4): 262–74. doi: 10.1097/PAP.0000000000000387.
3. Attanoos R.L., Churg A., Galateau-Salle F., Gibbs A.R., Roggli V.L. Malignant Mesothelioma and Its Non-Asbestos Causes. Arch Pathol Lab Med. 2018; 142(6):753–60. doi: 10.5858/arpa.2017-0365-RA.
4. Butnor K.J., Rueckert J., Pavlisko E.N., Sporn T.A., Roggli V.L. Malignant peritoneal mesothelioma in patients with endometriosis. J Clin Pathol. 2018; 71(11): 971–74. doi: 10.1136/jclinpath-2018-205099.
5. Butnor K.J., Pavlisko E.N., Sporn T.A., Roggli V.L. Malignant peritoneal mesothelioma and Crohn disease. J Clin Pathol. 2017; 70(3): 228–32. doi: 10.1136/jclinpath-2016-203945.
6. Boussios S., Moschetta M., Karathanasi A., Tsiouris A.K., Kanellos F.S., Tatsi K., Katsanos K.H., Christodoulou D.K. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol. 2018; 31(6): 659–69. doi: 10.20524/aog.2018.0305.
7. Husain A.N., Colby T.V., Ordóñez N.G., Allen T.C., Attanoos R.L., Beasley M.B., Butnor K.J., Chirieac L.R., Churg A.M., Dacic S., Galateau-Sallé F., Gibbs A., Gown A.M., Krausz T., Litzky L.A., Marchevsky A., Nicholson A.G., Roggli V.L., Sharma A.K., Travis W.D., Walts A.E., Wick M.R. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018; 142(1): 89–108. doi: 10.5858/arpa.2017-0124-RA.
8. Nicholson A.G., Sauter J.L., Nowak A.K., Kindler H.L., Gill R.R., Remy-Jardin M., Armato S.G. 3rd, Fernandez-Cuesta L., Bueno R., Alcala N., Foll M., Pass H., Attanoos R., Baas P., Beasley M.B., Brcic L., Butnor K.J., Chirieac L.R., Churg A., Courtiol P., Dacic S., De Perrot M., Frauenfelder T., Gibbs A., Hirsch F.R., Hiroshima K., Husain A., Klebe S., Lantuejoul S., Moreira A., Opitz I., Perol M., Roden A., Roggli V., Scherpereel A., Tirode F., Tazelaar H., Travis W.D., Tsao M.S., van Schil P., Vignaud J.M., Weynand B., Lang-Lazdunski L., Cree I., Rusch V.W., Girard N., Galateau-Salle F. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020; 15(1): 29–49. doi: 10.1016/j.jtho.2019.08.2506.
9. Marchevsky A.M., LeStang N., Hiroshima K., Pelosi G., Attanoos R., Churg A., Chirieac L., Dacic S., Husain A., Khoor A., Klebe S., Lantuejoul S., Roggli V., Vignaud J.M., Weynard B., Sauter J., Henderson D., Nabeshima K., Galateau-Salle F. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol. 2017; 67: 160–68. doi: 10.1016/j.humpath.2017.07.015.
10. Grishin N.A., Sidorov D.V., Vashakmadze L.A., Sokolov V.V., Filonenko E.V., Rubtsova N.A., Kolobaev I.V., Suleimanov E.A. A case of successful combined treatment in female patient with malignant epithelioid mesothelioma of the peritoneum. P.A. Herzen Journal of Oncology. 2017; 6(6): 52–54. (in Russian). doi: 10.17116/onkolog20176652-54. EDN: YLAURS.
Review
For citations:
Kopeyka S.M., Aksarin A.A., Babenko M.Y. Peritoneal mesotheioma. Cytoreductive surgery and HIPEC. Siberian journal of oncology. 2025;24(3):198-204. (In Russ.) https://doi.org/10.21294/1814-4861-2025-24-3-198-204
Views:
43
Email this article 
